Novartis US’ Post

Chronic lymphocytic leukemia (CLL) is a slow-growing blood cancer that forms in B-cells, causing the cancerous cells to multiply faster than the healthy ones. With advancements in science and treatment options, the life expectancy for these patients has increased dramatically in the past 10 years.       At Johnson & Johnson, our work is not done. We are continuing to innovate as we move from treatments to cures: https://bit.ly/3Xjhwn5   #EHA2024 #JNJOncology

On September 17, 2024, the FDA approved Keytruda (pembrolizumab) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM). https://lnkd.in/epKG4fzB Keytruda Updated Prescribing Information https://lnkd.in/ePb9vbV The recommended pembrolizumab dose is 200 mg every 3 weeks or 400 mg every 6 weeks until disease progression or unacceptable toxicity for up to 2 years. #Cancer #Oncology #Keytruda #pembrolizumab #Mesothelioma #PleuralMesothelioma #MPM #Immunotherapy #CheckPointInhibitors #PD1 #PD1Antibody #Moffitt #MoffittCancerCenter Moffitt Cancer Center

The National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS). RYTELO™ (imetelstat) is now recommended as a Category 1 and 2A treatment for symptomatic anemia in patients with lower-risk #MDS. This update follows the recent FDA’s approval in June 2024 of #RYTELO (imetelstat) for adult patients with low- to intermediate-1 risk MDS who are transfusion-dependent and who have not responded to, lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs). Read the full press release here: https://shorturl.at/ZG5bk #Research #BloodCancer

The FDA grants a breakthrough therapy designation to ziftomenib for the treatment of patients with relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). This is the first investigational treatment to be granted this designation in NPM1-mutant AML. Ziftomenib is a menin-MLL inhibitor that prevents the interaction of two proteins, menin and KMT2A/MLL, that, when fused together, are responsible for survival and proliferation of certain kinds of leukemia cells. NPM1-mutant AML represents approximately 30% of new AML cases annually, and this designation reflects that NPM1-mutant AML is a disease of significant unmet need for which there is no approved targeted therapy as well as the fact that ziftomenib offers potential to demonstrate substantial improvement over available therapies. #Cancer #Oncology #Ziftomenib #Leukemia #LeukemiaAwareness #AcuteMyeloidLeukemia #AML #Moffitt #MoffittCancerCenter Moffitt Cancer Center

🚨FDA Approves Obecabtagene Autoleucel for Relapsed/Refractory B-ALL FDA Approves Obecabtagene Autoleucel for Relapsed/Refractory B-ALL On November 8, 2024, the FDA approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.) for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). This second-generation CD19-directed CAR T-cell therapy demonstrated promising efficacy in clinical trials, with 42% of patients achieving complete remission within three months. Learn more about its mechanism and clinical implications: https://lnkd.in/dkbpiVdv Mark Geyer American Association for Cancer Research #Cancer #Leukemia #ALL #MedEd #MedNews #Health #Medicine #OncoDaily #Oncology 

This post is intended for a US audience only. I’m at the American Society of Hematology (ASH) 2024 Annual Meeting with many of my AstraZeneca and Alexion colleagues to learn about the latest challenges and scientific advances in #bloodcancer, as well as share the contributions we are making in hematology. Today, interim results from our AMPLIFY Phase III study for patients living with chronic lymphocytic leukemia (#CLL) were showcased in the ASH Annual Meeting Press Program and will take center stage during an oral presentation tomorrow. CLL is one of the most common types of leukemia in adults, with an estimated 20,700 new cases diagnosed in the United States this year. This disease remains incurable and chronic, requiring long-term management. Our work is driven by our goal of changing the practice of medicine and transforming the lives of patients living with blood cancer. I’m proud to share how we’re working toward this for CLL during tomorrow’s presentation. Read more here: https://lnkd.in/e3meS3QK #USOnly #AstraZenecaUS #ASH24

Aneuploidies, which are changes in the numbers of whole chromosomes or chromosome arms, are common in cancer, but their contributions to cancer cell survival have been difficult to pinpoint. Girish et al. developed a chromosome-engineering tool to orchestrate the targeted loss of aneuploid chromosome arms and thereby compare isogenic cancer cell lines with and without selected trisomies.

Aneuploidies, which are changes in the numbers of whole chromosomes or chromosome arms, are common in cancer, but their contributions to cancer cell survival have been difficult to pinpoint. Girish et al. developed a chromosome-engineering tool to orchestrate the targeted loss of aneuploid chromosome arms and thereby compare isogenic cancer cell lines with and without selected trisomies.

Aneuploidies, which are changes in the numbers of whole chromosomes or chromosome arms, are common in cancer, but their contributions to cancer cell survival have been difficult to pinpoint. Girish et al. developed a chromosome-engineering tool to orchestrate the targeted loss of aneuploid chromosome arms and thereby compare isogenic cancer cell lines with and without selected trisomies.

At present, treating high-risk patients with #TP53-mutated #myeloid #malignancies remains an area of unmet need 🤔 In an interview from #ASCO24, David Sallman, MD, Moffitt Cancer Center, discusses updates in this area 🎥 🩸 Trials with #eprenetapopt (APR-246) and #magrolimab have been unsuccessful, leaving frontline treatment for these high-risk patients an unmet need Ongoing Phase III trials are investigating #venetoclax (VERONA; NCT04401748) and #tamibarotene 💡 Additionally, novel combinations, new anti-#CD47 agents, and weekly dosing schedules are being explored to improve outcomes Learn more 👉 https://lnkd.in/dA6FhSTf #VJHemOnc #Hematologynews